Core Viewpoint - bioAffinity Technologies, Inc. (BIAF) has experienced a significant decline in stock value following its third-quarter 2025 results, with shares dropping 21.8% since the earnings release, compared to a 2.2% loss in the S&P 500 Index during the same period [1] Financial Performance - In Q3 2025, bioAffinity reported total revenues of $1.4 million, a decrease of 38.5% from $2.4 million in the same quarter last year, due to a strategic exit from unprofitable pathology services and a focus on CyPath Lung commercialization [2] - CyPath Lung testing revenue increased by 122% year-over-year, driven by higher case volumes and increased physician adoption, particularly within Veterans Administration (VA) medical centers [2] - Operating expenses fell by 13.5% to $3.7 million from $4.3 million, primarily due to lower laboratory-related costs, but the net loss widened to $5.1 million from $2 million a year ago, largely due to non-cash expenses related to warrant revaluations [3] - Loss per share slightly narrowed to $4.74 from $4.84 [3] Operational Metrics - Direct costs decreased by 34.6% year-over-year to $0.9 million from $1.4 million, reflecting efficiency initiatives [4] - Selling, general, and administrative expenses decreased by 6.6%, while depreciation and amortization expenses dropped by 25.1% [4] - Research and development (R&D) spending rose by 20.4%, and clinical development costs increased by 52.9% due to expanded preclinical and clinical work [4] Growth and Adoption - Test volumes for CyPath Lung increased by 97% in the first nine months of 2025 compared to the prior year, with a record quarterly sales level in Q3 2025, climbing 92% from the previous quarter [5] - Management emphasized the importance of marketing initiatives targeting the VA health system, which have shown positive traction [7] Balance Sheet and Cash Position - Cash and equivalents improved significantly to $7.7 million from $1.1 million at year-end 2024, supported by $10.4 million in gross proceeds from equity transactions during the quarter [6] Strategic Focus and Future Plans - Management outlined strategic objectives for 2025, including expanding the sales team, engaging with major VA medical centers, and increasing marketing efforts [11] - The company is advancing companion diagnostic candidates for asthma and chronic obstructive pulmonary disease (COPD), targeting an estimated $26 billion global market [12] Governance and Intellectual Property - bioAffinity strengthened its governance with new board appointments and regained full Nasdaq Capital Market compliance [13] - The company added another U.S. patent protecting its proprietary algorithm used in CyPath Lung, marking its second consecutive quarter of patent portfolio expansion [13]

Core Insights - Merus NV's shares increased by 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition deal, which includes the addition of the breakthrough therapy Petosemtamab to Genmab's late-stage pipeline [1] Gainers - Steakholder Foods Ltd rose 92% to $8.32 after announcing an agreement to acquire Twine Solutions [4] - JFB Construction Holdings surged 77.4% to $12.15 following a $44 million private placement announcement [4] - Plus Therapeutics gained 24.3% to $0.77 after securing a national coverage agreement with UnitedHealthcare for its CNSide assay [4] - Avalo Therapeutics rose 24.1% to $13.40 after a previous decline of 6% [4] - Enanta Pharmaceuticals gained 22.7% to $9.69 ahead of presenting topline results from its Phase 2b study of Zelicapavir for RSV [4] - Canopy Growth Corp jumped 19.4% to $1.60 [4] - Zura Bio Ltd gained 18.3% to $2.85 after a 15% increase on Friday [4] - Tilray Brands surged 17.4% to $1.35, with first-quarter financial results to be announced on October 9 [4] - Larimar Therapeutics jumped 16.4% to $5.93, with an update on the Nomlabofusp program scheduled for September 2 [4] Losers - MoonLake Immunotherapeutics dipped 86.3% to $8.50 despite achieving statistically significant results in its Phase 3 VELA trials [4] - Maris Tech fell 37.3% to $2.62 after reporting a H1 loss of 30 cents per share [4] - Sunrise New Energy Co Ltd shares dipped 28.1% to $0.88 after a previous 10% gain [4] - Cycurion Inc declined 15.5% to $0.28 after a significant drop of over 30% on Friday [4] - bioAffinity Technologies dipped 14.4% to $4.53 after a 55% increase on Friday [4] - Youxin Technology Ltd fell 13.9% to $0.058 following a 1-for-80 reverse split announcement [4] - Top KingWin Ltd declined 12.8% to $4.07 after a previous 48% increase [4] - Cellectis SA fell 10.4% to $3.01 [4] - Quantum-Si Inc decreased 10.1% to $1.34 after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc fell 8.4% to $24.00 [4]

Market Performance - U.S. stocks traded higher, with the Dow up 0.83% to 46,328.48, the NASDAQ rising 0.45% to 22,484.92, and the S&P 500 gaining 0.62% to 6,645.73 [1] - Energy shares increased by 1.4%, while information technology stocks fell by 0.4% [1] Commodity Prices - Oil prices rose by 1.7% to $66.10, gold increased by 0.9% to $3,805.00, silver was up 1.8% to $45.945, and copper fell by 0.4% to $4.7390 [5] European Market Trends - European shares showed positive performance, with the eurozone's STOXX 600 gaining 0.66%, Spain's IBEX 35 Index rising 1.28%, London's FTSE 100 up 0.71%, Germany's DAX 40 gaining 0.66%, and France's CAC 40 climbing 0.78% [6] Asian Market Trends - Asian markets closed lower, with Japan's Nikkei 225 down 0.87%, Hong Kong's Hang Seng declining 1.35%, China's Shanghai Composite falling 0.65%, and India's BSE Sensex down 0.90% [7] Company News - MEDIROM Healthcare Technologies Inc. shares surged 106% to $2.9791 after announcing plans to deploy Orb across 100 Japanese relaxation studios [9] - bioAffinity Technologies, Inc. shares increased by 73% to $5.92 following the release of additional case studies demonstrating the effectiveness of CyPath Lung in detecting Stage 1A lung cancer [9] - Datavault AI Inc. shares rose 55% to $1.2890 after securing a $150 million investment in Bitcoin to build a supercomputer [9] - Pop Culture Group Co., Ltd shares dropped 53% to $0.9718 after entering a registered direct offering to sell 5 million shares at $1.20 per share [9] - Kuke Music Holding Limited shares fell 36% to $0.7507 after acquiring a controlling interest in Naxos Music Group [9] - Lexaria Bioscience Corp. shares decreased by 27% to $1.1187 after pricing a $4 million registered direct offering at $1.50 per share [9] Economic Indicators - U.S. personal spending rose by 0.6% month-over-month to $21.112 trillion in August, while personal income increased by 0.4% to $26.280 trillion [11] - The Personal Consumption Expenditures price index rose 2.7% year-over-year in August, marking the highest reading since February 2025 [11] - The University of Michigan consumer sentiment was revised lower to 55.1 in September from a preliminary reading of 55.4 and down from 58.2 in August [11]

Market Performance - U.S. stocks experienced gains, with the Dow up 0.83% to 46,328.48, the NASDAQ rising 0.45% to 22,484.92, and the S&P 500 increasing 0.62% to 6,645.73 [1] - Energy shares saw a notable increase of 1.4%, while information technology stocks fell by 0.4% [1] Commodity Prices - Oil prices rose by 1.7% to $66.10, gold increased by 0.9% to $3,805.00, silver was up 1.8% to $45.945, while copper fell by 0.4% to $4.7390 [5] European Market Trends - European shares showed positive movement, with the eurozone's STOXX 600 gaining 0.66%, Spain's IBEX 35 Index rising 1.28%, London's FTSE 100 up 0.71%, Germany's DAX 40 increasing by 0.66%, and France's CAC 40 climbing 0.78% [6] Asian Market Trends - Asian markets closed lower, with Japan's Nikkei 225 down 0.87%, Hong Kong's Hang Seng declining 1.35%, China's Shanghai Composite falling 0.65%, and India's BSE Sensex decreasing by 0.90% [7] Company News - MEDIROM Healthcare Technologies Inc. shares surged 106% to $2.9791 following plans to deploy Orb across 100 Japanese relaxation studios and expand to 200 locations [9] - bioAffinity Technologies, Inc. saw a 73% increase in shares to $5.92 after releasing additional case studies demonstrating the effectiveness of CyPath Lung in detecting Stage 1A lung cancer [9] - Datavault AI Inc. shares rose 55% to $1.2890 after securing a $150 million investment in Bitcoin to build a supercomputer [9] - Pop Culture Group Co., Ltd shares dropped 53% to $0.9718 after entering a registered direct offering to sell 5 million shares at $1.20 each [9] - Kuke Music Holding Limited shares fell 36% to $0.7507 following its acquisition of a controlling interest in Naxos Music Group [9] - Lexaria Bioscience Corp. shares decreased by 27% to $1.1187 after pricing a $4 million registered direct offering at $1.50 per share with $1.34 warrants in a concurrent private placement [9]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 250 points, closing at 46,213.26, a rise of 0.58% [1] - The NASDAQ rose by 0.31% to 22,455.17, and the S&P 500 gained 0.47% to 6,636.07 [1] - Energy shares saw a notable increase of 1%, while consumer staples stocks fell by 0.3% [1] Inflation and Economic Indicators - The Personal Consumption Expenditures (PCE) price index, the Federal Reserve's preferred inflation gauge, rose by 2.7% year-over-year in August, slightly above July's 2.6% [2][3] - Monthly PCE inflation accelerated to 0.3% in August, up from 0.2% in July [3] - Personal spending in the U.S. increased by 0.6% month-over-month to $21.112 trillion in August, exceeding market estimates [13] - U.S. personal income rose by 0.4% month-over-month to $26.280 trillion in August, also above market expectations [13] Commodity Market - Oil prices increased by 0.7% to $65.44, while gold rose by 0.5% to $3,789.00 [6] - Silver saw a rise of 1.4% to $45.725, whereas copper fell by 0.7% to $4.7240 [6] European Market Performance - European shares showed positive performance, with the eurozone's STOXX 600 gaining 0.8% [7] - Spain's IBEX 35 Index rose by 1.1%, London's FTSE 100 increased by 0.8%, Germany's DAX 40 gained 0.8%, and France's CAC 40 climbed 0.9% [7] Company-Specific Movements - MEDIROM Healthcare Technologies Inc. saw a significant share price increase of 155% to $3.74 following its expansion plans [9] - BioAffinity Technologies, Inc. shares surged by 92% to $6.57 after releasing additional case studies related to lung cancer detection [9] - Datavault AI Inc. shares rose by 50% to $1.2510 after securing a $150 million investment in Bitcoin [9] - Pop Culture Group Co., Ltd experienced a drop of 52% to $0.9802 due to a registered direct offering [9] - Kuke Music Holding Limited shares fell by 31% to $0.8111 after acquiring a controlling interest in Naxos Music Group [9] - Lexaria Bioscience Corp. shares decreased by 27% to $1.11 following a registered direct offering announcement [9] Asian Market Performance - Asian markets closed lower, with Japan's Nikkei 225 falling by 0.87%, Hong Kong's Hang Seng declining by 1.35%, China's Shanghai Composite down by 0.65%, and India's BSE Sensex falling by 0.90% [10]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 250 points, closing at 46,213.26, a rise of 0.58% [1] - The NASDAQ rose by 0.31% to 22,455.17, and the S&P 500 gained 0.47% to 6,636.07 [1] - Energy shares saw a notable increase of 1%, while consumer staples stocks fell by 0.3% [1] Inflation and Economic Indicators - The Personal Consumption Expenditures (PCE) price index, the Federal Reserve's preferred inflation gauge, rose by 2.7% year-over-year in August, slightly above July's 2.6% [2][3] - Monthly PCE inflation accelerated to 0.3% in August, up from 0.2% in July [3] - Personal spending in the U.S. increased by 0.6% month-over-month to $21.112 trillion in August, surpassing market estimates [13] - U.S. personal income rose by 0.4% month-over-month to $26.280 trillion in August, also above market expectations [13] Commodity Market - Oil prices increased by 0.7% to $65.44, while gold rose by 0.5% to $3,789.00 [6] - Silver saw a rise of 1.4% to $45.725, whereas copper fell by 0.7% to $4.7240 [6] European Market Performance - European shares showed positive performance, with the eurozone's STOXX 600 gaining 0.8% [7] - Spain's IBEX 35 Index rose by 1.1%, London's FTSE 100 increased by 0.8%, Germany's DAX 40 gained 0.8%, and France's CAC 40 climbed by 0.9% [7] Company-Specific Movements - MEDIROM Healthcare Technologies Inc. shares surged by 155% to $3.74 following the announcement of expansion plans [9] - bioAffinity Technologies, Inc. saw a 92% increase in shares to $6.57 after releasing additional case studies [9] - Datavault AI Inc. shares rose by 50% to $1.2510 after securing a $150 million investment in Bitcoin [9] - Pop Culture Group Co., Ltd shares dropped by 52% to $0.9802 due to a registered direct offering [9] - Kuke Music Holding Limited shares fell by 31% to $0.8111 after acquiring a controlling interest in Naxos Music Group [9] - Lexaria Bioscience Corp. shares decreased by 27% to $1.11 following a registered direct offering announcement [9] Asian Market Performance - Asian markets closed lower, with Japan's Nikkei 225 falling by 0.87%, Hong Kong's Hang Seng declining by 1.35%, China's Shanghai Composite down by 0.65%, and India's BSE Sensex falling by 0.90% [10]

As filed with the Securities and Exchange Commission on September 25, 2025. Registration No. 333-290480 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO 3300 Nacogdoches Road Suite 216 San Antonio, Texas 78217 (210) 698-5334 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as sp ...

As filed with the Securities and Exchange Commission on September 24, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 46-5211056 (I.R.S. Employer Identification Number) 3300 N ...

As filed with the Securities and Exchange Commission on August 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 3300 Nacogdoches Road Suite 216 San Antonio, Texas 78217 (210) 698-5334 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8731 46-5211056 (Primary Standard Industrial Class ...

Core Viewpoint - bioAffinity Technologies, Inc. (BIAF) has experienced a significant decline in stock value following its second-quarter 2025 earnings release, with an 11% drop since the report and a 27.4% decline over the past month, contrasting with the S&P 500's performance [1][2]. Financial Performance - For Q2 2025, bioAffinity reported revenues of $1.3 million, a 47.1% decrease from $2.4 million in the same quarter last year, primarily due to the discontinuation of unprofitable pathology services [2]. - Testing revenue from the CyPath Lung diagnostic test increased by 62.3% year-over-year in the first half of 2025, reaching $323,000 from $199,000, indicating growing physician adoption [2]. - Operating expenses decreased by 15.6% to $3.8 million from $4.5 million a year earlier, but the net loss widened to $4.1 million, or $0.17 per share, compared to a loss of $2.1 million, or $0.19 per share, in Q2 2024 [3]. - The accumulated deficit increased to $60.4 million, with total stockholders' deficit at $2.1 million as of June 30, 2025 [5]. Cost Management - Direct costs fell by 27.8% year-over-year, and research and development spending decreased by 22.6% to $0.3 million [4]. - Clinical development expenses surged by 151.2% to $129,279, reflecting increased professional fees for advancing CyPath Lung toward pivotal trials [4]. - Selling, general, and administrative expenses were reduced by 10.4% to $2.2 million, aided by efficiencies from integrating Precision Pathology Laboratory Services [4]. Strategic Initiatives - CEO Maria Zannes highlighted the acceleration of the CyPath Lung commercialization strategy, supported by real-world case studies demonstrating its effectiveness in detecting early-stage lung cancers [6]. - A price increase for CyPath Lung to $2,900 was implemented to align with private payer reimbursement, and a logistics partnership with Cardinal Health OptiFreight was established to enhance sample delivery reliability [7]. - The company has expanded its intellectual property portfolio with new patents in the U.S., China, Canada, and Australia [7][10]. Market Positioning - The decline in revenue was attributed to a strategic exit from lower-margin pathology services, allowing a focus on high-margin diagnostics [8]. - CyPath Lung achieved record sales in June and July, indicating strong market traction [8]. - Management aims to broaden distribution into new regions and health systems while advancing next-generation diagnostic and therapeutic platforms [9].